| |
Pamela Sklar, M.D., Ph.D.
Address:
Massachusetts General Hospital
Harvard Medical School
Simches Research Building,
185 Cambridge Street,
Boston, MA 02114
Phone Number: (617) 726-0475
Email: sklar@chgr.mgh.harvard.edu
Adminstrative contact: Jarred Knapp
Phone: (617) 643-3667
jknapp@partners.org
|
Dr. Sklar is a neuroscientist, human geneticist and psychiatrist. She completed clinical training in Psychiatry at Columbia Presbyterian Hospital and the New York State Psychiatric Institute in Manhattan and research training in the laboratories of Solomon Snyder (Johns Hopkins Medical School) and Richard Axel (Columbia University). Her primary laboratory is located in the Psychiatric and Neurodevelopmental Genetics Unit (PNGU) in the Center for Human Genetic Research at Massachusetts General Hospital, where she is an associate professor of psychiatry and the associate director of the PNGU. Dr. Sklar is also a senior associate member of the Broad Institute, as well as a founding member of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard where she serves as director of genetics.p>
The Sklar laboratory focuses on identification of susceptibility genes for psychiatric diseases and has played a leading role in identification rare structural variants in schizophrenia, common variants associated with bipolar disorder, and the highly polygenic nature of schizophrenia and bipolar disorder. Working closely with PNGU statistical geneticist Shaun Purcell, there is a strong focus on the development of novel methods for genetic analyses including gene-based and pathway based tests, imputation, segmental sharing (rare variants), epistasis, predictive modeling, and exploration of the genetic factors contributing to treatment response in particular as applied to bipolar disorder and schizophrenia. New avenues of research in the lab include exploration of the role of rare variation in psychiatric disease using next-generation whole genome sequencing in schizophrenia and bipolar disorder, pioneering the use of iPS technology as cellular models of schizophrenia and bipolar disorder with defined human genetic liability, detecting epigenetic changes in schizophrenia and bipolar disorder, exploratory work investigating environmental contribution and follow-up biological investigations of novel genetic associations.
Reference Links
|
